gptkbp:instance_of
|
gptkb:immunotherapy
|
gptkbp:administered_by
|
oral tablet
|
gptkbp:approves
|
gptkb:2006
gptkb:FDA
|
gptkbp:available_in
|
gptkb:various_countries
|
gptkbp:brand
|
gptkb:Atripla
|
gptkbp:clinical_trial
|
Phase III trials
|
gptkbp:clinical_use
|
long-term management of HIV
|
gptkbp:contains
|
gptkb:tenofovir_disoproxil_fumarate
gptkb:efavirenz
gptkb:emtricitabine
|
gptkbp:contraindication
|
pregnancy
severe liver disease
|
gptkbp:dosage_form
|
once daily
|
gptkbp:drug_interactions
|
CYP450 inducers
CYP450 inhibitors
|
gptkbp:financial_support
|
available for adherence support
|
gptkbp:formulation
|
fixed-dose combination
|
gptkbp:healthcare
|
gptkb:tablet
requires prescription
|
https://www.w3.org/2000/01/rdf-schema#label
|
Atripla
|
gptkbp:indication
|
HIV-1 infection
|
gptkbp:is_monitored_by
|
liver function tests
renal function tests
|
gptkbp:marketed_as
|
gptkb:Bristol-Myers_Squibb
|
gptkbp:mechanism_of_action
|
non-nucleoside reverse transcriptase inhibitor
|
gptkbp:packaging
|
blister pack
|
gptkbp:patient_education
|
importance of adherence
|
gptkbp:patient_population
|
adults and children over 12 years
|
gptkbp:pharmacokinetics
|
once daily dosing
inhibits HIV replication
|
gptkbp:previous_name
|
efavirenz/emtricitabine/tenofovir
|
gptkbp:price
|
varies by country
|
gptkbp:provides_guidance_on
|
part of combination therapy
recommended in treatment-naive patients
|
gptkbp:regulatory_compliance
|
approved in many countries
|
gptkbp:requires
|
available online
|
gptkbp:research
|
ongoing studies for long-term effects
|
gptkbp:safety_features
|
generally well tolerated
|
gptkbp:side_effect
|
dizziness
fatigue
nausea
rash
lactic acidosis
neuropsychiatric symptoms
|
gptkbp:storage
|
room temperature
|
gptkbp:supply_chain
|
managed by pharmaceutical companies
|
gptkbp:treatment
|
reduces viral load
improves CD4 count
|
gptkbp:type_of_care
|
important for efficacy
|
gptkbp:used_for
|
treatment of HIV
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
|
gptkbp:bfsLayer
|
4
|